Literature DB >> 7683358

5-Aza-2'-deoxycytidine (Decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: past, present and future trends.

A Pinto1, V Zagonel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 7683358

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  34 in total

1.  Effect of 5-Aza-2'-deoxycytidine on the P16 tumor suppressor gene in hepatocellular carcinoma cell line HepG2.

Authors:  L H Liu; W H Xiao; W W Liu
Journal:  World J Gastroenterol       Date:  2001-02       Impact factor: 5.742

2.  Mechanisms of 5-azacytidine (5AzC)-induced toxicity in the rat foetal brain.

Authors:  Masaki Ueno; Kei-Ichi Katayama; Hiroyuki Nakayama; Kunio Doi
Journal:  Int J Exp Pathol       Date:  2002-06       Impact factor: 1.925

Review 3.  Promising approaches in acute leukemia.

Authors:  J Cortes; H M Kantarjian
Journal:  Invest New Drugs       Date:  2000-02       Impact factor: 3.850

4.  Characterization of permeability, stability and anti-HIV-1 activity of decitabine and gemcitabine divalerate prodrugs.

Authors:  Christine L Clouser; Laurent Bonnac; Louis M Mansky; Steven E Patterson
Journal:  Antivir Chem Chemother       Date:  2014-12-16

5.  Epigenetic differences in cytogenetically normal versus abnormal acute myeloid leukemia.

Authors:  Elizabeth A Griffiths; Steven D Gore; Craig M Hooker; Helai P Mohammad; Michael A McDevitt; B Douglas Smith; Judith E Karp; James G Herman; Hetty E Carraway
Journal:  Epigenetics       Date:  2010-10-01       Impact factor: 4.528

6.  A prospective multicenter observational study of decitabine treatment in Korean patients with myelodysplastic syndrome.

Authors:  Je-Hwan Lee; Jun Ho Jang; Jinny Park; Seonyang Park; Young-Don Joo; Yeo-Kyeoung Kim; Hoon-Gu Kim; Chul Won Choi; Sung-Hyun Kim; Seong Kyu Park; Eunkyung Park; Yoo Hong Min
Journal:  Haematologica       Date:  2011-06-09       Impact factor: 9.941

7.  An integrated genomic and epigenomic approach predicts therapeutic response to zebularine in human liver cancer.

Authors:  Jesper B Andersen; Valentina M Factor; Jens U Marquardt; Chiara Raggi; Yun-Han Lee; Daekwan Seo; Elizabeth A Conner; Snorri S Thorgeirsson
Journal:  Sci Transl Med       Date:  2010-10-20       Impact factor: 17.956

8.  Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia.

Authors:  Elias Jabbour; Sergio Giralt; Hagop Kantarjian; Guillermo Garcia-Manero; Madan Jagasia; Partow Kebriaei; Leandro de Padua; Elizabeth J Shpall; Richard Champlin; Marcos de Lima
Journal:  Cancer       Date:  2009-05-01       Impact factor: 6.860

9.  Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells.

Authors:  Jonathan C Cheng; Daniel J Weisenberger; Felicidad A Gonzales; Gangning Liang; Guo-Liang Xu; Ye-Guang Hu; Victor E Marquez; Peter A Jones
Journal:  Mol Cell Biol       Date:  2004-02       Impact factor: 4.272

10.  Transbuccal delivery of 5-aza-2 -deoxycytidine: effects of drug concentration, buffer solution, and bile salts on permeation.

Authors:  Ravichandran Mahalingam; Harish Ravivarapu; Sanjeev Redkar; Xiaoling Li; Bhaskara R Jasti
Journal:  AAPS PharmSciTech       Date:  2007-07-13       Impact factor: 3.246
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.